Pictet Asset Management (UK)’s Maravai LifeSciences MRVI Stock Holding History

Pictet Asset Management (UK)’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$217K	Buy	+5,191	New	+$201K	﹤0.01%	1596

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Pictet Asset Management (UK)'s MRVI Position: Q2 2021 in Review

Pictet Asset Management (UK) opened a new position in Maravai LifeSciences (MRVI) in Q2 2021: 5,191 shares worth $217K. The stake represents ﹤0.01% of the portfolio and ranks #1596 among its holdings.

196 funds tracked by Wall St. Rank hold MRVI as of Q2 2021.

Pictet Asset Management (UK) held 5,191 shares of Maravai LifeSciences worth $217K as of Q2 2021.
Maravai LifeSciences was a new Pictet Asset Management (UK) position in Q2 2021.
Maravai LifeSciences made up ﹤0.01% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #1596 holding.
196 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.